Amyloid-PET quantification through the tracer-independent Centiloid (CL) scale has emerged as an essential tool for the accurate measurement of amyloid-β (Aβ) pathology in Alzheimer's disease (AD) patients. The AMYPAD consortium set out to integrate existing literature and recent work from the consortium to provide clinical context-of-use recommendations for the CL scale. Compared to histopathology, visual reads, and cerebrospinal fluid, CL quantification accurately reflects the amount of AD pathology. With high certainty, a CL value below 10 excludes the presence of Aβ pathology, while a value above 30 corresponds well with pathological amounts. Values falling in between these two cutoffs (“intermediate range”) are related to an increased risk of disease progression. Together, CL quantification is a valuable adjunct to visual assessments of amyloid-PET images. An abnormal amyloid biomarker assessment is a key criterion to determine eligibility for anti-amyloid disease-modifying therapies, and amyloid-PET quantification can add further value by precisely monitoring amyloid clearance, and hence guiding patient management decisions.

中文翻译：

---

来自 AMYPAD 联盟的临床使用环境的 Centiloid 建议


通过示踪剂非依赖性 Centiloid （CL） 量表进行淀粉样蛋白 PET 定量已成为准确测量阿尔茨海默病 （AD） 患者β淀粉样蛋白 （Aβ） 病理的重要工具。AMYPAD 联盟着手整合现有文献和联盟的最新工作，为 CL 量表提供临床使用环境建议。与组织病理学、肉眼读取和脑脊液相比，CL 定量准确反映了 AD 病理的数量。具有高质量证据，CL 值低于 10 排除了 Aβ 病理的存在，而高于 30 的值与病理量非常吻合。介于这两个临界值（“中间范围”）之间的值与疾病进展风险增加有关。总之，CL 定量是淀粉样蛋白 PET 图像视觉评估的宝贵辅助手段。淀粉样蛋白生物标志物评估异常是确定抗淀粉样蛋白疾病修饰疗法资格的关键标准，淀粉样蛋白 PET 定量可以通过精确监测淀粉样蛋白清除率来进一步增加价值，从而指导患者管理决策。